CRESCENT BIOPHARMA, INC. Balance Sheet
CBIO|5 years of annual SEC 10-K data (FY2014-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 5 fiscal years. All figures from audited SEC 10-K filings.
CRESCENT BIOPHARMA, INC. had $240M in total assets and $203M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|
| Cash & Equivalents | $213.2M | $40.0M | $55.2M | $2.3M | $17.4M |
| Accounts Receivable | $18.0M | - | - | - | - |
| Current Assets | $236.7M | $127.2M | $40.5M | $47.2M | $56.1M |
| PP&E (Net) | $846.0K | $1.1M | $1.1M | $521.4K | $452.3K |
| Total Assets | $240.3M | $128.6M | $42.4M | $48.5M | $57.3M |
| Current Liabilities | $36.1M | $8.2M | $6.3M | $7.7M | $6.5M |
| Shareholders' Equity | $203.0M | $40.5M | $50.8M | $2.9M | $12.5M |